Isolation, structure, and biological activity of several metabolites of delta-9-tetrahydrocannabinol

An emerging trend in Novel Psychoactive Substances (NPSs): designer THC

Since its discovery as one of the main components of cannabis and its affinity towards the cannabinoid receptor CB1, serving as a means to exert its psychoactivity, Δ9-tetrahydrocannabinol (Δ9-THC) has inspired medicinal chemists throughout history to create more potent derivatives. Initially, the goal was to synthesize chemical probes for investigating the molecular mechanisms behind the pharmacology of Δ9-THC and finding potential medical applications. The unintended consequence of this noble intent has been the proliferation of these compounds for recreational use. This review comprehensively covers the most exhaustive number of THC-like cannabinoids circulating on the recreational market. It provides information on the chemistry, synthesis, pharmacology, analytical assessment, and experiences related to the psychoactive effects reported by recreational users on online forums. Some of these compounds can be found in natural cannabis, albeit in trace amounts, while others are entirely artificial. Moreover, to circumvent legal issues, many manufacturers resort to semi-synthetic processes starting from legal products extracted from hemp, such as cannabidiol (CBD). Despite the aim to encompass all known THC-like molecules, new species emerge on the drug users' pipeline each month. Beyond posing a significantly high public health risk due to unpredictable and unknown side effects, scientific research consistently lags behind the rapidly evolving recreational market.

The 2-Norbornyl Cation is not a Single Minimum Energy System

Simple and dual variable linear regression equations are presented which can estimate the sensitivity constants ρ for the solvolysis reactions of hundreds of bicyclic and tricyclic compounds. These are the first QSARs which utilize dihedral angles to estimate/predict ρ constants. These QSARs and other analyses herein support the new theory that the bridgehead hydrogen bond orbital assists the displacement of the exo leaving group in the solvolyses of 2-norbornyl derivatives. Alternative interpretions of the 1H NMR and 13C NMR spectra indicate that C1 is hypercoordinated rather than C6. Consequently, in normal hydroxylic solvents the 2-norbornyl cation is not symmetrical, does not require C—C σ-bond bridging and is not a single minimum energy system, i.e. it is a pair of rapidly equilibrating cations, eq 1, structure 2b. At ≤ −158°C, the 2-norbornyl cation is proposed to be an H—C1—H σ-bond delocalized resonance hybrid structure 16/16’. Hypotheses are presented which suggest that the norbornane system can be viewed as a saturated counterpart of a conjugated π system, e.g. benzene. This new delocalization and bond concept, sigma aromaticity, can also help to explain the preferential “exo'’ reactions of norbornane and norbornene systems, the unusual stability of the 2-norbornyl cation, and perhaps provide new insight concerning the ubiquitousness of six-membered rings. Sigma aromaticity may also help account for the greater efficiency of singlet energy transfer between chromophores when the molecular spacer group is rigid rather than flexible, and electron transfer in DNA.

Estimation of measurement uncertainty for the quantification of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid and its glucuronide in urine using liquid chromatography-tandem mass spectrometry

Recently, the estimation of the measurement uncertainty has become a significant issue in the quality control of forensic drug testing. In the present study, the uncertainty of the measurement was calculated for the quantification of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) and its glucuronide conjugate (THC-COOH-glu) in urine using liquid chromatography-tandem mass spectrometry. The procedure was based on liquid-liquid extraction of a volume of urine (800 µL) with ethyl acetate. The sources of uncertainty were identified and classified into four major categories as follows: standard preparation, calibration curve, method precision and bias. The overall contribution of combined standard uncertainty on THC-COOH increased in the order of standard preparation (0.9%), method precision (10.4%), calibration curve (30.3%) and bias (58.4%) and, while calibration curve (53.0%) and bias (40.4%) gave the bigger contributions to the combined standard uncertainty for THC-COOH-glu than method precision and standard preparation, which accounted for 6.3 and 0.3%, respectively. The reliability of a measurement was expressed by stating the expanded uncertainty of the measurement result at 95% confidence level. The concentrations of THC-COOH and THC-COOH-glu in the urine sample with their expanded uncertainties were 10.20 ± 1.14 ng/mL and 25.42 ± 5.01 ng/mL, respectively.

Quantification of Δ9-tetrahydrocannabinol and its Major Metabolites in Meconium by Gas Chromatographic-mass Spectrometric Assay: Assay Validation and Preliminary Results of the “Meconium Project”

A rapid and simple procedure based on gas chromatography-mass spectrometry (GC-MS) is described for determination of Delta-tetrahydrocannabinol (THC), 11-hydroxy-Delta-tetrahydrocannabinol (THC-OH) and 11-nor-Delta-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in meconium using Delta-tetrahydrocannabinol (Delta-THC) and deuterated THC-COOH as internal standards. The biological matrix was subjected to liquid-liquid extraction after enzyme hydrolysis for conjugated analytes.Chromatography was performed on a fused silica capillary column and analytes were determined in the selected-ion-monitoring (SIM) mode. The method was validated in the range 20 to 500 microg/g using 1g of meconium per assay. The method was applied to the analysis of meconium in a cohort of newborns to assess eventual fetal exposure to cannabis. Within positive samples, THC-COOH and THC-OH (range: 33.7 to 182.1 and 20.7 to 493.3 microg/g, respectively) were both present in the majority of cases with only 1 specimen with THC-OH as the most abundant metabolite and 2 with THC only.

Simultaneous determination of cannabidiol, cannabinol, and \gD9-tetrahydrocannabinol in human hair by gas chromatography-mass spectrometryin human hair by gas chromatography-mass spectrometry

An analytical method was developed for evaluating the cannabidiol (CBD), cannabinol (CBN), and delta9-tetrahydrocannabinol (delta9-THC) level in human hair using gas chromatography-mass spectrometry (GC-MS). Hair samples (50 mg) were washed with isopropyl alcohol and cut into small fragments (< 1 mm). After adding a deuterated internal standard, the hair samples were incubated in 1.0 M NaOH for 10 min at 95 degrees C. The analytes from the resulting hydrolyzed samples were extracted using a mixture of n-hexane-ethyl acetate (75:25, v/v). The extracts were then evaporated, derivatized, and injected into the GC-MS. The recovery ranges of CBD, CBN, and delta9-THC at three concentration levels were 37.9-94.5% with good correlation coefficients (r2 >0.9989). The intra-day precision and accuracy ranged from -9.4% to 17.7%, and the inter-day precision and accuracy ranged from -15.5% to 14.5%, respectively. The limits of detection (LOD) for CBD, CBN, and delta9-THC were 0.005, 0.002, and 0.006 ng/mg, respectively. The applicability of this method of analyzing the hair samples from cannabis abusers was demonstrated.

Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes in the liver of male mice

Drug-metabolizing enzymes play a great role in the bioactivation and also detoxification of zenobiotics and carcinogens such as N-nitrosamines and polycyclic aromatic hydrocarbons (PAHs). Therefore, the present study was undertaken to investigate the effect of narcotic drugs such as cannabis (hashish) and diacetylmorphine (heroin) on the activity of N-nitrosodimethylamine N-demethylase I [NDMA-dI], arylhydrocarbon [benzo(a)pyerne] hydroxylase [AHH], cytochrome P450 (CYP), cytochrome b(5), NADPH-cytochrome c reductase, glutathione-S-transferase, and levels of glutathione and thiobarbituric acid-reactive substances (TBARS). In addition, the present study showed the influence of hashish and heroin after single (24 h) and repeated-dose treatments (4 consecutive days) on the expression of cytochrome P450 2E1 (CYP 2E1) and cytochrome P450 2C6 (CYP 2C6). The expression of CYP 2E1 was slightly induced after single-dose and markedly induced after repeated dose-treatments of mice with hashish (10 mg kg(-1) body weight). Contrarily, heroin markedly induced the expression of CYP 2C6 after single-dose and potentially reduced this expression after repeated-dose treatments. It is believed that N-nitrosamines are activated principally by CYP 2E1 and in support of this, the activity of NDMA-dI was found to be increased after single- and repeated-dose treatments of mice with hashish by 23 and 41%, respectively. In addition, single- and repeated-dose treatments of mice with hashish increased: (1) the total hepatic content of CYP by 112 and 206%, respectively; (2) AHH activity by 110 and 165%, respectively; (3) NADPH-cytochrome c reductase activity by 21 and 98%, respectively; (4) and glutathione level by 81 and 173%, respectively. Also, single-dose treatments of mice with heroin increased the total hepatic content of CYP, AHH, NADPH-cytochrome c reductase, and glutathione level by 126, 72, 39, 205%, respectively. However, repeated dose-treatments of mice with heroin did not change such activities except cytochrome c reductase activity increased by 20%. Interestingly, the level of free radicals, TBARS, was potentially decreased after single or repeated-dose treatments with either hashish or heroin. It is clear from this study that the effects of hashish are different from those of heroin on the above mentioned enzymes particularly after repeated dose treatments. It is concluded that hashish induced the expression of CYP 2E1 and other carcinogen-metabolizing enzymes activities, and this induction could potentiate the deleterious effects of N-nitrosamines and aromatic hydrocarbons, e.g. benzo(a)pyrene, upon the liver and probably other organs. Such alterations may also change the therapeutic actions of other drugs, which are primarily metabolized by the P450 system, when administered to peoples using hashish or heroin.

A historical overview of chemical research on cannabinoids

The chemical research on the plant cannabinoids and their derivatives over two centuries is concisely reviewed. The tortuous path leading to the discovery of the endogenous cannabinoids is described. Future directions, which will probably be followed are delineated.

Sex difference in the oxidative metabolism of delta 9-tetrahydrocannabinol in the rat

Oxidative metabolism of delta 9-tetrahydrocannabinol (THC), one of the major components of marihuana, was studied using liver microsomes of adult male and female rats. There was no significant difference in the rates of the cannabinoid oxidation in terms of nmol per min per nmol of liver microsomal cytochrome P450 or of nmol per min per mg of microsomal protein between male and female rats. delta 9-THC was biotransformed to various metabolites including 11-hydroxy-delta 9-THC (11-OH-delta 9-THC), 8 alpha-OH-delta 9-THC, 8 alpha,11-diOH-delta 9-THC, 3'-OH-delta 9-THC by liver microsomes of male rats, while it was oxidized selectively to 11-OH-delta 9-THC by liver microsomes of female rats. After intraperitoneal administration of delta 9-THC, various metabolites were again found in the liver of the male rat, while in the female rat oxidation of the methyl group at the 9-position was a major metabolic pathway. These results demonstrate that an apparent sex-related difference exists in the oxidative metabolism of delta 9-THC in the rat.

The mass spectra of the trimethylsilyl derivatives of the hydroxy and acid metabolites of delta 1- and delta 6-tetrahydrocannabinol

Deuterium labelling and high resolution mass measurements have been used to investigate the fragmentation mechanisms leading to diagnostic ions in the mass spectra of the trimethylsilyl derivatives of 58 hydroxy and acid metabolites of delta 1- and delta 6-tetrahydrocannabinol and of two related compounds, 2 alpha- and 2 beta-hydroxy-delta 6-tetrahydrocannabinol. The spectra of most of the hydroxy metabolites contained abundant ions which were characteristic of the position of hydroxy substitution. These could be used diagnostically to determine the structures of polysubstituted metabolites.

Acidic metabolites of delta1-tetrahydrocannabinol isolated from rabbit urine

The in vivo metabolism of delta1-tetrahydrocannabinol (delta1-THC) was investigated in the rabbit after i.v. administration. Thirteen acidic metabolites were isolated from rabbit urine and identified by gas chromatography-mass spectrometry and by proton magnetic resonance spectroscopy. One additional metabolite was tentatively identified. All but three were new metabolites and all but one were oxidized in the pentyl side chain. The metabolites included dicarboxylic acids, monocarboxylic acids and mono- or dihydroxylated derivatives thereof. However, the dicarboxylic acid metabolites were the most prominent.

More acidic metabolites of delta1-tetrahydrocannabinol isolated from rabbit urine

The in vivo metabolism of delta1-tetrahydrocannabinol (delta1-THC) was further investigated in the rabbit after i.v. administration. Nine acidic metabolites were isolated from a previously not investigated fraction of the urine and identified by gas chromatography-mass spectrometry and by proton magnetic resonance spectroscopy. The major metabolites were side-chain hydroxylated monocarboxylic acids. Three side-chains monocarboxylic acids hydroxylated in allylic positions in the isoprene moiety were also characterized. The metabolites 4''-hydroxy-delta1-THC-7-oic acid and 7-hydroxy-4'',5''-bisnor-delta1-THC-3''-oic acid were hitherto not identified. An earlier described dicarboxylic metabolite was present in high concentration. Further, the identity of an O-glucuronide as an in vivo urinary metabolite of delta1-THC was here for the first time unambiguously established by m.s. and p.m.r.

Pharmacokinetics of delta9-tetrahydrocannabinol in dogs

The pharmacokinetics of intravenously administered 14C-delta9-tetrahydrocannabinol and derived radiolabeled metabolites were studied in three dogs at two doses each at 0.1 or 0.5 and 2.0 mg/kg. Two dogs were biliary cannulated; total bile was collected in one and sampled in the other. The time course for the fraction of the dose per milliliter of plasma was best fit by a sum of five exponentials, and there was no dose dependency. No drug was excreted unchanged. The mean apparent volume of distribution of the central compartment referenced to total drug concentration in the plasma was 1.31 +/- 0.07 liters, approximately the plasma volume, due to the high protein binding of 97%. The mean metabolic clearance of drug in the plasma was 124 +/- 3.8 ml/min, half of the hepatic plasma flow, but was 4131 +/- 690 ml/min referenced to unbound drug concentration in the plasma, 16.5 times the hepatic plasma flow, indicating that net metabolism of both bound and unbound drug occurs. Apparent parallel production of several metabolites occurred, but the pharmacokinetics of their appearance were undoubtedly due to their sequential production during liver passage. The apparent half-life of the metabolic process was 6.9 +/- 0.3 min. The terminal half-life of delta9-tetrahydrocannabinol in the pseudo-steady state after equilibration in an apparent overall volume of distribtuion of 2170 +/- 555 liters referenced to total plasma concentration was 8.2 +/- 0.23 days, based on the consistency of all pharmacokinetic data. The best estimate of the terminal half-life, based only on the 7000 min that plasma levels could be monitored with the existing analytical sensitivity, was 1.24 days. However, this value was inconsistent with the metabolite production and excretion of 40-45% of dose in feces, 14-16.5% in urine, and 55% in bile within 5 days when 24% of the dose was unmetabolized and in the tissue at that time. These data were consistent with an enterohepatic recirculation of 10-15% of the metabolites. Intravenously administered radiolabeled metabolites were totally and rapidly eliminated in both bile and urine; 88% of the dose in 300 min with an apparent overall volume of distribution of 6 liters. These facts supported the proposition that the return of delta9-tetrahydrocannabinol from tissue was the rate-determining process of drug elimination after initial fast distribution and metabolism and was inconsistent with the capability of enzyme induction to change the terminal half-life.

Dihydroxylated metabolites of cannabinol formed by rat liver in vitro

Cannabinol (CBN) was metabolized in vitro by a 10,000 g supernatant from rat liver. After removal of unchanged CBN and its monohydroxylated metabolites four dihydroxylated metabolites were isolated. By nuclear magnetic resonance and mass spectrometry the compounds were identified as 1'',7-dihydroxy-CBN. Side chain hydroxylation occurred predominantly at C-4'' anc C-3''.

Dioxygenated metabolites of cannabidiol formed by rat liver

The metabolism of cannabidiol (CBD) was studied in vitro using a 10 000 g supernatant from rat liver. After removal of unchanged CBD and its monohydroxylated metabolites, a polar fraction remained from which ten dioxygenated metabolites were isolated. Mass spectrometry and nuclear magnetic resonance spectroscopy were used to identify the following metabolites: 6,7-dihydroxy-CBD, 1 inch,7-dihydroxy-CBD, 3 inch,7-dihydroxy-CBD, 4 inch,7-dihydroxy-CBD, 5 inch,7-dihydroxy-CBD, 2 inch,6-dihydroxy-CBD, 3 inch,6beta-dihydroxy-CBD, 4 inch, 6beta-dihydroxy-CBD (tentative), 3 inch-hydroxy-6-oxo-CBD, and 4 inch-hydroxy-6-oxo-CBD. The abundance of isolated dihydroxy metabolites reflected the quantity of monohydroxy metabolites that was previously found. In both series, 7-hydroxylation occurred to the greatest extent. Side chain hydroxylation occurred predominantly at C-4 inch and to a lesser degree at C-3 inch. Trace amounts of metabolites were hydroxylated at C-1 inch,-2 inch, or 5 inch.

Identification of monohydroxylated metabolites of cannabidiol formed by rat liver

Cannabidiol (CBD) was metabolized in vitro by rat liver enzymes. Unchanged CBD and eight monohydroxylated metabolites were isolated and positively identified. As previously reported, 7-hydroxy-CBD was the major metabolite. The second most abundant metabolite was 6alpha-hydroxy-CBD; whereas only a trace amount of 6beta-hydroxy-CBD was found. In addition hydroxylation occurred in all positions of the pentyl side chain, 4 inches-hydroxy-CBD being most abundant. 3 inches-Hydroxy-CBD was formed in half of the yield of 4 inches-hydroxy-CBD, while 1 inches-, 2 inches-, 5 inches-hydroxy-CBD were each formed in approximately one fourth of the yield of 4 inches-hydroxy-CBD.

The distribution of delta1-tetrahydrocannabinol and 7-hydroxy-delta-tetrahydrocannabinol in the mouse brain after intraventricular injection

Δ1-Tetrahydrocannabinol (Δ1-THC) and 7-hydroxy-Δ1-THC were injected into the cerebral ventricles of mice by an improved technique, and the potencies of the drugs were measured by the mouse catalepsy test. Both drugs were found to have the same activity when administered by this route as after intravenous injection. Autoradiographic experiments with tritium-labelled compounds showed that at the time of the peak behavioural effect almost all the injected dose of 3H-Δ1-THC (1.6 mg kg−1) or 3H-7-hydroxy-Δ1-THC (0.6 mg kg−1) remained in the intraventricular space and had not penetrated the brain tissue. Δ1-THC was found to remain in the ventricles after the behavioural effect had disappeared; 3% of the injected dose was still present 2 days after injection of 3H-Δ1-THC (1.6 mg kg−1).

Plasma protein binding of 7-hydroxy- 1-tetrahydrocannabinol: an active 1-tetrahydrocannabinol metabolite

7-Hydroxy-Δ1-tetrahydrocannabinol, which is a pharmacologically and psychologically active metabolite of Δ1-tetrahydrocannabinol in man, has been shown by equilibrium dialysis and ultrafiltration to be bound 94–99% to plasma proteins. Further experiments, using the [14C]labelled compound, with agarose and Polyacrylamide gel electrophoresis and ultracentrifugation suggest that albumin, α1-lipoprotein and, to a minor degree, also β-lipoprotein are involved in the protein binding of 7-hydroxy-Δ1-tetrahydrocannabinol in blood plasma.

Delta-9-tetrahydrocannabinol: localization in body fat

[(14)C]Delta(9)-Tetrahydrocannabinol (Delta(9)THC) was injected subcutaneously in rats every day for 1 to 26 days. Concentrations of Delta(9)THC and its metabolites, 11-hydroxytetrahydrocannabinol and 8,11-dihydroxytetrahydrocannabinol, were determined in various tissues. After a single injection, the concentration of Delta(9)THC in fat was ten times greater than in any other tissue examined, and persisted in this tissue for 2 weeks. With repeated injection, Delta(9)THC and its metabolites accumulated in fat and brain.